Recently, Zhou et al. demonstrated that Pirfenidone, an Food and Drug Administration (FDA)-approved TGF-β/collagen-targeted drug, attenuated the post-COVID-19 pulmonary fibrosis manifestation (36). Here, TGFB1 is linked to pulmonary fibrosis.